Latest News and Press Releases
Want to stay updated on the latest news?
-
18 December 2025 DXS INTERNATIONAL PLC (AQSE: DXSP) Notice of Cyber Security Incident The Board of DXS International plc (“the Company” or “DXSP”), the AQSE Growth Market quoted healthcare...
-
TORONTO and HAIFA, Israel, Nov. 28, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a preclinical-stage biotechnology company...
-
TORONTO and HAIFA, Israel, Nov. 03, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) announced today that it has been accepted to...
-
TORONTO and HAIFA, Israel and INDIANAPOLIS, Sept. 16, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical...
-
TORONTO and HAIFA, Israel, Aug. 28, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a preclinical-stage biotechnology company...
-
TORONTO and HAIFA, Israel, Aug. 20, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) is pleased to announce new preclinical imaging...
-
DXS INTERNATIONAL PLC (AQSE: DXSP) ExpertCare selected for prestigious Grow Digital Health Midlands Programme DXS International plc ("DXS" or the "Company"), the digital clinical decision support...
-
NurExone Announces Clinical Trial Plans for Acute Spinal Cord Injury Therapy at Annual Meeting of American Spinal Injury Association
-
NurExone Expands European Engagement with Investor Events in Germany and Switzerland
-
NurExone Biologic Announces U.S. Uplisting Intention and Closes C$2.3 Million Private Placement